1. 22 abstracts accepted for obefazimod at ECCO 2026 highlight key findings. 2. Oral presentation reveals anti-fibrotic potential, addressing unmet needs in IBD. 3. Phase 3 ABTECT trials show efficacy and safety across diverse patient populations. 4. Preclinical data indicates significant improvements in inflammatory bowel disease treatment. 5. Management emphasizes importance of new findings at upcoming international congress.
FAQ
Why Bullish?
The acceptance of numerous abstracts and promising preclinical findings signify strong clinical interest, potentially enhancing market sentiment for ABVX. Historical precedents show that similar announcements lead to positive stock movements for biotech companies, notably when new therapeutic potentials are validated.
How important is it?
The article presents crucial upcoming data and its strategic significance at a prominent congress, which bolsters investor expectations around ABVX's growth and therapeutic impact. Its clear significance in the potential treatment of major unmet medical needs further amplifies this relevance.
Why Long Term?
The upcoming ECCO event and its potential scientific endorsements could improve ABVX's visibility and investor confidence over time. Long-term therapy developments in major diseases tend to cultivate steady investor interest until tangible outcomes, akin to successes seen with companies like Gilead after F болезнейlle antiviral approvals.
Abivax Advances Research on Obefazimod at ECCO 2026 with 22 Accepted Abstracts
PARIS, France – December 17, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX), a clinical-stage biotechnology company, has announced the acceptance of 22 scientific abstracts pertaining to obefazimod, aimed at treating inflammatory bowel disease (IBD). These findings will be showcased at The European Crohn’s and Colitis Organization’s (ECCO) 21st Annual Congress, scheduled for February 18-21, 2026, in Stockholm, Sweden. This news underscores Abivax's commitment to advancing its research in chronic inflammatory diseases.
Significant Contributions to IBD Research
The 22 accepted abstracts comprise 1 oral presentation, 5 digital oral presentations, and 16 posters, reflecting a substantial dataset that demonstrates obefazimod's efficacy and safety profile. The data draw upon analyses from the Phase 3 ABTECT Induction Trials focused on moderate-to-severely active ulcerative colitis (UC).
- 1 oral presentation highlighting novel findings on anti-fibrotic activity.
- 5 digital presentations covering clinical trial data.
- 16 posters showcasing additional safety and efficacy data.
Novel Anti-Fibrotic Findings in Inflammatory Bowel Disease
Among the highlights of the congress will be an oral presentation titled, “Obefazimod shows first evidence of anti-fibrotic activity in preclinical models of inflammatory bowel disease," scheduled for February 21, 2026. This pivotal presentation will detail groundbreaking preclinical data, addressing fibrosis—a serious complication in Crohn's disease (CD) that often leads to surgical interventions.
Current therapies have yet to provide effective solutions for fibrosis in IBD patients, making these findings particularly relevant.
Insights from the ABTECT Induction Trials
The accepted abstracts indicate that obefazimod displays clinical activity across diverse patient groups. They reveal:
- Downregulation of pro-inflammatory cytokines (IL-17A, IL-6).
- Early symptomatic improvement alongside clinically meaningful benefits.
- A favorable safety and tolerability profile for obefazimod.
Statements from Abivax Leadership
Marc de Garidel, Chief Executive Officer of Abivax, expressed his enthusiasm: “We are highly enthusiastic about the strong presence of obefazimod data at the 21st ECCO Congress, highlighting the impactful and robust data we have generated in inflammatory bowel disease.” He further noted that presenting 22 abstracts signifies the depth of clinical understanding derived from the ABTECT Induction Trials.
Dr. Fabio Cataldi, Chief Medical Officer, emphasized the importance of these findings, stating, “Intestinal fibrosis is a major complication of Crohn’s disease that is not fully addressed by current therapies.” He looks forward to engaging the IBD scientific community with new insights on the anti-fibrotic properties of obefazimod and its efficacy and safety in UC.
Presentation Schedule for Obefazimod at ECCO 2026
The following is the detailed presentation schedule for obefazimod at ECCO 2026:
| Date & Time | Session | Room | Abstract # | Title | Presenter |
|---|---|---|---|---|---|
| Sat, Feb 21, 08:40–08:50 | Holistic IBD Care - Session 10 | Plenary Hall | OP30 | Obefazimod shows first evidence of anti-fibrotic activity in preclinical models of inflammatory bowel disease | Prof. Silvio Danese, MD, PhD |